IESC vs. VRNA

Last updated Jun 9, 2026

IESC (IES Holdings, Inc.) and VRNA (Verona Pharma plc) are both stocks. IESC operates in Engineering & Construction (Industrials), while VRNA operates in Biotechnology (Healthcare). At a 0.15 correlation, their price movements are largely independent.

Performance

IESC vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in IES Holdings, Inc. (IESC) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

IESC

• 1D: 1.97%
• 1M: 10.23%
• YTD: 88.91%
• 6M: 66.06%
• 1Y: 162.49%
• 3Y*: 140.27%
• 5Y*: 69.06%
• 10Y*: 48.95%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IESC vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
IESC IES Holdings, Inc.	88.91%	93.58%	153.67%	122.72%	-29.76%	9.99%	79.42%	65.02%	-9.86%	-13.75%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between IESC and VRNA is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.04
Correlation (3Y) Calculated over the trailing 3-year period	0.21
Correlation (5Y) Calculated over the trailing 5-year period	0.18
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.15

The correlation between IESC and VRNA shifts across timeframes, from 0.04 (1 year) to 0.21 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap IESC : $14.83B VRNA : $9.72B
EPS IESC : $18.85 VRNA : -$0.69
PS Ratio IESC : 4.08 VRNA : 57.97
PB Ratio IESC : 13.83 VRNA : 34.92
Total Revenue (TTM) IESC : $3.63B VRNA : $167.65M
Gross Profit (TTM) IESC : $931.31M VRNA : $159.52M
EBITDA (TTM) IESC : $487.14M VRNA : -$40.86M

Return for Risk

IESC vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IESC

IESC Risk / Return Rank: 92
IESC Sharpe Ratio Rank: 94
IESC Sortino Ratio Rank: 88
IESC Omega Ratio Rank: 88
IESC Calmar Ratio Rank: 96
IESC Martin Ratio Rank: 96

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IESC vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for IES Holdings, Inc. (IESC) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IESC	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	2.64	—	—
Sortino ratio: Return per unit of downside risk	2.84	—	—
Omega ratio: Gain probability vs. loss probability	1.39	—	—
Calmar ratio: Return relative to maximum drawdown	7.50	—	—
Martin ratio: Return relative to average drawdown	21.33	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IESC	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.64	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	1.29	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	1.02	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.05	—	—

Drawdowns

Drawdown Indicators

	IESC	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-98.32%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-21.80%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-49.23%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-54.22%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-54.28%	—	—
Current Drawdown Current decline from peak	-0.97%	—	—
Average Drawdown Average peak-to-trough decline	-55.01%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	7.66%	—	—

Volatility

Volatility by Period

	IESC	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.77%	—	—
Volatility (6M) Calculated over the trailing 6-month period	49.79%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	62.06%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	53.94%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	48.10%	—	—

Dividends

IESC vs. VRNA - Dividend Comparison

Neither IESC nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

IESC vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between IES Holdings, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

IESC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, IES Holdings, Inc. reported a gross profit of 238.70M and revenue of 974.20M. Therefore, the gross margin over that period was 24.5%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

IESC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, IES Holdings, Inc. reported an operating income of 112.30M and revenue of 974.20M, resulting in an operating margin of 11.5%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

IESC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, IES Holdings, Inc. reported a net income of 110.00M and revenue of 974.20M, resulting in a net margin of 11.3%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both IESC and VRNA in my portfolio?

IESC and VRNA have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.